Login to Your Account

Chiron, GSK Enter Agreement For Obesity Pathway Research

By Randall Osborne

Thursday, January 9, 2003
Several months after the company cut three late-stage programs, Chiron Corp. has set about the business of building its pipeline, nailing down a small-molecule partnership with GlaxoSmithKline plc to fuel research in the melanocortin 4 receptor pathway. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription